|Bid||24.97 x 800|
|Ask||25.09 x 800|
|Day's range||24.19 - 25.57|
|52-week range||15.58 - 48.40|
|Beta (5Y monthly)||1.07|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Castle Biosciences, Inc. ( NASDAQ:CSTL ) shareholders should be happy to see the share price up 11% in the last week...
Castle Biosciences, Inc. (CSTL) delivered earnings and revenue surprises of -10% and 7.73%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
The FDA clears Vertex's (VRTX) Investigational New Drug application for VX-634, a small molecule AAT corrector, thereby allowing the company to initiate a first-in-human clinical study in healthy volunteers.